HHS intends to expand use of buprenorphine in treatment for opioid use disorder by easing a requirement that has often been cited as an 'administrative burden.'
and even when they did:
Prescribing Buprenorphine for Pain
Neither the CSA nor its implementing regulations expressly prohibit the prescribing and dispensing of buprenorphine or other opiate products for the treatment of pain. Federal regulations do require that controlled substances be prescribed for a legitimate medical purpose by a DEA registered practitioner acting in the usual course of his or her professional practice. 21 CFR 1306.04(a). If a DEA registered practitioner issues a prescription for a buprenorphine drug product approved by the FDA for the treatment of pain, or off-label prescribes a buprenorphine drug product approved by the Food and Drug Administration (FDA) for maintenance or detoxification treatment for the treatment of pain, then the UIN or “X” Number is not required. Please note that the specific prescribing or dispensing of certain buprenorphine products for pain may be considered “off-label” use. DEA cannot address any possible consequences under the Food, Drug, and Cosmetic Act (FD&C) for dispensing for unapproved (off-label) uses.
This site uses cookies to help personalize content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies and terms of service.